High Soluble Amyloid‐β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations

Manuscript Number: 

22-0808

Author(s): 
Samir EL Andaloussi, Roberto Cilia, Alok K. Dwivedi, Alberto J. Espay, Kariem Ezzat, Neill Graff-Radford, Emily J. Hill, Tarja Malm, Hiroshi Mori, Georg Nübling, Lon S. Schneider, Jennifer S. Sharma, Andrea Sturchio, Per Svenningsson, Matthew J.A. Wood

Disclosures

Samir EL Andaloussi

  • Consulting Fees:
    in the SAB for evox therapeutics. Not relevant to the current work
    Equity:
    Cofounder of REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies
    Patents/Royalties
    Cofounder of REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies

Roberto Cilia

  • Consulting Fees:
    BIAL SpA
    Lecture Fees:
    Zambon; Zambon SAU; Bial Italia Srl

Alok K. Dwivedi

  • Nothing to Disclose

Alberto J. Espay

  • Consulting Fees:
    I have received personal compensation as a consultant/scientific advisory board member for Neuroderm, Neurocrine, Amneal, Acadia, Acorda, Bexion, Kyowa Kirin, Sunovion, Supernus (formerly, USWorldMeds), Avion Pharmaceuticals, and Herantis Pharma
    Patents/Royalties
    I am co-owner of a patent that covers synthetic soluble nonaggregating peptide analogs as replacement treatments in proteinopathies.

Kariem Ezzat

  • Equity:
    Cofounder of REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies
    Patents/Royalties
    Cofounder of REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies

Neill Graff-Radford

  • Grants
    • Agency: 
      Esai
    • Agency: 
      Biogen
    • Agency: 
      Lilly

Emily J. Hill

  • Nothing to Disclose

Tarja Malm

  • Equity:
    Equity: Cofounder of REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies
    Patents/Royalties
    Patents/Royalties Cofounder of REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies

Hiroshi Mori

  • Nothing to Disclose

Georg Nübling

  • Nothing to Disclose

Lon S. Schneider

  • Consulting Fees:
    AC Immune, Alpha-cognition, Athira, BioVie, Lilly/Avid, Cognition Inc, Cortexyme, Eisai, GW Research, ImmunoBrain Checkpoint Ltd, Merck, Neurim Ltd, Otsuka/Lundbeck, Pharmatrophix, Roche/Genentech
    Grants
    • Agency: 
      Alzheimer's Association Part the Cloud
      Dates: 
      2022
    • Agency: 
      Eli Lilly
      Dates: 
      2022
    • Agency: 
      Roche/Genentech
      Dates: 
      2020
    • Agency: 
      Biogen
      Dates: 
      2022
    • Agency: 
      Novartis
      Dates: 
      2019
    • Agency: 
      Biohaven
      Dates: 
      2021
    • Agency: 
      Washington University/NIA DIAN-TU
      Dates: 
      2022

Jennifer S. Sharma

  • Nothing to Disclose

Andrea Sturchio

  • Equity:
    Cofounded REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies, that covers synthetic soluble non-aggregating peptide analogues as replacement treatment in proteinopathies.
    Patents/Royalties
    Cofounded REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies, that covers synthetic soluble non-aggregating peptide analogues as replacement treatment in proteinopathies.

Per Svenningsson

  • Lecture Fees:
    Lecture honorarium from Zambon,

Matthew J.A. Wood

  • Consulting Fees:
    Co-founder and consultant to Pepgen and Evox Therapeutics
    Equity:
    Co-founder of Pepgen and Evox Therapeutics
    Patents/Royalties
    Inventor on patents related to cell penetrating peptides and exosome therapeutics